Pompe Disease Pipeline Analysis Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Asklepios, Astellas, BioMarin, Amicus Therapeutics, Spark Therapeutics, Rocket Pharma, Audentes, Immusoft, Oxyrane

Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, about 15+ key pharma and biotech companies are working on 20+ pipeline drugs in the Pompe Disease therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

"Pompe Disease Pipeline Insight, 2023" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Pompe Disease Therapeutics Market.

The report provides a detailed description of the Pompe Disease drugs, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any). The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.

Get a Detailed Overview of the Pompe Disease Clinical Trial Activities and Regulatory Developments in the domain:
https://www.delveinsight.com/report-store/pompe-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Pompe Disease Pipeline Analysis
The report provides insights into:
• The report provides detailed insights into the key companies that are developing Pompe Disease therapies.
• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Pompe Disease treatment.
• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• It navigates the emerging Pompe Disease drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement in the Pompe Disease treatment market.

Learn More about the Clinical and Commercial Development Activities in the Pompe Disease Therapeutics Domain:
https://www.delveinsight.com/report-store/pompe-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Pompe Disease Therapeutics Analysis
The treatment is disease-specific, symptomatic, and supportive. Enzyme replacement therapy (ERT) is the mainstay of treatment and involves administering synthetic GAA enzymes into the body to compensate for the deficiency. Recently, the US FDA approved Sanofi's NEXVIAZYME (avalglucosidase alfa) for the treatment of patients one year of age and older with late-onset Pompe disease. Besides this, Sanofi's LUMIZYME/MYOZYME is also approved. Amicus
Therapeutics POMBILITI (cipaglucosidase alfa) and OPFOLDA (miglustat) have recently been approved in EU4 and the UK for late-onset Pompe disease. Additional treatment is symptomatic and supportive and involves physical, occupational, speech, and respiratory therapy.

Though enzyme-replacement has significantly extended the lifespan of patients, and improved morbidity, the results have not fully met expectations, and many patients continue to be burdened by the disease. Therapies are being developed by Amicus, Astellas Pharma, Asklepios Biopharmaceutical, Spark Therapeutics, etc. that have the potential to address the current unmet treatment needs and change the market paradigm in the future.

There are approx. 15+ key companies are developing therapies for Pompe Disease. Currently, Amicus Therapeutics is leading the therapeutics market with its Pompe Disease drug candidates in the most advanced stage of clinical development.

Pompe Disease Companies in the Therapeutics Market Include:
• Asklepios Biopharmaceutical
• Astellas Pharma Inc
• BioMarin Pharmaceutical
• Amicus Therapeutics
• Spark Therapeutics
• Maze Therapeutics
• Denali Therapeutics
• Rocket Pharmaceuticals
• Audentes Therapeutics
• Immusoft
• Oxyrane
And Many Others

Emerging and Marketed Pompe Disease Therapies Covered in the Report Include:
• AT-GAA: Amicus Therapeutics
• SPK-3006: Spark Therapeutics
• MZE 001: Maze Therapeutics
• SPK-3006: Spark Therapeutics
• M 021: M6P Therapeutics
• AAV2/8LSPhGAA: Asklepios Biopharmaceutical
• SPK-3006: Spark Therapeutics
• Cipaglucosidase alfa: Amicus Therapeutics
And Many more

Get an in-depth Assessment of the Emerging Therapies and Pompe Disease Companies Actively Working in the Market @
https://www.delveinsight.com/sample-request/pompe-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

The Report Covers the Emerging Pompe Disease Therapies Under Different Phases of Clinical Development Like -
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued and inactive candidates

Route of Administration
Pompe Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Intravenous
• Subcutaneous
• Oral
• Intramuscular

Molecule Type
Products have been categorized under various Molecule types such as
• Monoclonal antibody
• Small molecule
• Peptide

Request for Sample PDF to Understand More About the Pompe Disease Treatment Outlook and Future Perspectives @
https://www.delveinsight.com/sample-request/pompe-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content
1. Report Introduction
2. Executive Summary
3. Pompe Disease Current Treatment Patterns
4. Pompe Disease - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Pompe Disease Late-Stage Products (Phase-III)
7. Pompe Disease Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Pompe Disease Discontinued Products
13. Pompe Disease Product Profiles
14. Pompe Disease Companies
15. Pompe Disease Drugs
16. Dormant and Discontinued Products
17. Pompe Disease Unmet Needs
18. Pompe Disease Future Perspectives
19. Pompe Disease Analyst Review
20. Appendix
21. Report Methodology

Get Detailed Insights About the Reports Offerings @
https://www.delveinsight.com/sample-request/pompe-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Contact Info:
Shruti Thakur
Manager - Marketing & International Branding
Email: info@delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.